Merck will be hoping for better news from its own phase 3 trials of MK-7684A in lung cancer, which include KeyVibe-003 comparing the drug to Keytruda in previously-untreated PD-L1-positive NSCLC ...

For MSD, all eyes are now on KeyVibe-003, which is comparing the drug to Keytruda in previously-untreated PD-L1-positive NSCLC, as well as KeyVibe-006 and KeyVibe-007 looking at first-line use of ...